@entity955 is the most common @entity943 in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like @entity64 . As a result, @entity955 @entity1 are risk-stratified using the CHADS2 or CHA2DS2-VASc scoring systems. Those at intermediate-to-high risk have traditionally been treated with therapeutic anticoagulation with @entity1229 for @entity64 prevention. Although effective, @entity1229 use is fraught with multiple concerns, such as a narrow therapeutic window, drug-drug and @entity734 , and excessive @entity548 . Novel oral anticoagulant agents have recently become available as viable alternatives for @entity1229 therapy. Direct @entity556 inhibitor @entity3926 and factor Xa inhibitors like @entity3925 and @entity5424 have already been approved by the US Food and Drug Administration (FDA) for @entity64 prevention in @entity1 with nonvalvular @entity955 . @entity14242 is the latest oral direct factor Xa inhibitor studied in the largest novel oral anticoagulant trial so far: ENGAGE AF-TIMI 48. Treatment with a 30 mg or 60 mg daily dose of @entity14242 was found to be noninferior to dose-adjusted @entity1229 in reducing the rate of @entity64 and systemic @entity887 in @entity1 with nonvalvular @entity955 , with a lower incidence of @entity548 complications and @entity65 . @entity14242 was recently reviewed by an FDA advisory committee and recommended as a @entity64 -prophylaxis agent. Once approved, it promises to provide another useful alternative to @entity1229 therapy.

An evidence-based review of @entity14242 and its role in XXXX prevention in @entity1 with nonvalvular @entity955 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity556 :: ('2147', 'Gene') :: ['thrombin'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity3926 :: ('MESH:C554682', 'Chemical') :: ['dabigatran'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['apixaban'] @entity14242 :: ('MESH:C552171', 'Chemical') :: ['edoxaban', 'Edoxaban'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'Atrial fibrillation'] @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia'] @entity734 :: ('MESH:D019966', 'Disease') :: ['drug-food interactions'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular deaths'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity64 :: (MESH:D020521,Disease) :: ['stroke']
